1 Targeted Drug HER2 Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug HER2 Inhibitors for NSCLC
1.2 Classification of Targeted Drug HER2 Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Comparison by Types (2020-2025)
1.2.2 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Afatinib
1.2.4 Trastuzumab
1.2.5 Other
1.3 Global Targeted Drug HER2 Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug HER2 Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug HER2 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.5 Global Market Size of Targeted Drug HER2 Inhibitors for NSCLC (2015-2025)
2 Manufacturers Profiles
2.1 Boehringer-Ingelheim
2.1.1 Business Overview
2.1.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.2 Roche
2.2.1 Business Overview
2.2.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Roche Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.3 Mylan
2.3.1 Business Overview
2.3.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Mylan Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.4 Biocon
2.4.1 Business Overview
2.4.2 Targeted Drug HER2 Inhibitors for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biocon Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
3 Global Targeted Drug HER2 Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug HER2 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug HER2 Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.3 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.5 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2015-2019)
5.2 USA Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5.3 Canada Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5.4 Mexico Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2015-2019)
6.2 Germany Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.3 UK Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.4 France Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.5 Russia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.6 Italy Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2015-2019)
7.2 China Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.3 Japan Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.4 Korea Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.5 India Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2015-2019)
8.2 Brazil Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8.3 Argentina Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8.4 Colombia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Targeted Drug HER2 Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Countries (2015-2019)
9.2 Saudi Arabia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.3 UAE Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.4 Egypt Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.5 Nigeria Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.6 South Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
10 Global Targeted Drug HER2 Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Market Share by Type (2015-2019)
10.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Type (2020-2025)
10.3 Afatinib Revenue Growth Rate (2015-2025)
10.4 Trastuzumab Revenue Growth Rate (2015-2025)
10.5 Other Revenue Growth Rate (2015-2025)
11 Global Targeted Drug HER2 Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Application (2015-2019)
11.2 Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Application (2020-2025)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2015-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
12 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast (2020-2025)
12.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size Forecast (2020-2025)
12.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Regions (2020-2025)
12.3 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.4 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.6 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
